Tiziana life sciences has only fully human anti-cd3 mab in clinical studies, could be poised to improve care for patients with severe multiple sclerosis

London, uk / accesswire / april 19, 2023 / tiziana life sciences (nasdaq:tlsa), a london-based biotechnology company, is developing a first-in-class drug, foralumab. foralumab is the only fully human anti-cd3 monoclonal antibody (mab) at the clinical stage.

TLSA Ratings Summary

TLSA Quant Ranking